ArticleJournal of the American Heart Association2025
Evaluating the Prevalence of Optimal Neurodevelopmental Outcome at 2 Years in Children Previously on Ventricular Assist Device Support.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Neurocognitive, Social-Cognitive and Quality of Life Differences in Children with Advanced Heart Failure: A Single-Center Cross-Sectional Study.Children (Basel, Switzerland) · 2026Article
- Evaluating the Prevalence of Optimal Neurodevelopmental Outcome at 4.5-Years in Children Previously on Ventricular Assist Device Support.Pediatric transplantation · 2026Article
- Neurodevelopmental outcomes for pediatric ventricular assist device and heart transplant patients in the modern Era.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLiterature reporting neurodevelopmental outcomes for patients who undergo ventricular assist device (VAD) therapy is limited to posttransplant cohorts. This study aims to determine the prevalence of optimal neurodevelopmental outcome and factors associated with nonoptimal outcome in patients implanted with a VAD at ≤15 months of age.
methodsPatients followed by the Complex Pediatric Therapies Follow-Up Program were included in a prospective-inception cohort study if born between January 2006 and December 2022 and implanted with a VAD at ≤15 months of age. A modified optimal neurodevelopmental outcome was defined as scores of ≥80 on the Bayley Scales of Infant and Toddler Development and on the Adaptive Behavior Assessment System, and in the absence of cerebral palsy, permanent hearing loss, visual impairment, or seizure disorder. Firth multiple regression analysis was used to determine independent factors associated with nonoptimal outcome.
resultsA total of 56 patients underwent VAD implant at ≤15 months with neurodevelopmental assessments available for 39/40 patients who survived to 2 years. The mean age of VAD implant was 5.45 (SD 3.99) months, 69.2% were male, and 38.5% had congenital heart disease. Optimal neurodevelopmental outcome was seen in 25.6% of patients. Neurological insult (OR, 12.34 [95% CI, 1.29-1660.36],
conclusionsOptimal outcome was demonstrated in one quarter of patients who had a VAD at ≤15 months of age and underwent neurodevelopmental testing at 2 years of age. A potentially modifiable factor of neurological insult was demonstrated as being independently associated with nonoptimal outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.